Results 131 to 140 of about 166 (149)

A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners

Journal of Oncology Pharmacy Practice, 2020
Emma Foreman, Himanshu Patel, Joseph Bubalo   +2 more
exaly  

Economics as a guide to developing public policies for biosimilar pharmaceutical products

Queen Mary Journal of Intellectual Property, 2012
openaire   +1 more source

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

Expert Opinion on Drug Safety, 2013
Karen Macdonald, Ivo Abraham
exaly  

Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?

Diabetes Care, 2015
Philip Home, Home Philip
exaly  

Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage

Health Affairs, 2019
Daniel Weisdorf, Pinar Karaca-Mandic, Ronald Go   +2 more
exaly  

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

European Journal of Health Economics, 2014
Marta Péntek, Valentin Brodszky, Petra Baji   +2 more
exaly  

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Diabetes Care, 2015
Francesca Porcellati, Carmine Giuseppe Fanelli, Geremia Bolli   +2 more
exaly  

PHARMACEUTICALS Merck deal with South Korea’s Hanwha bolsters move into biosimilars

Chemical & Engineering News Archive, 2011
openaire   +1 more source

The Future of Biosimilar Insulins

Diabetes Spectrum, 2016
exaly  

Demonstration of Pharmacokinetic and Pharmacodynamic Equivalence in Healthy Volunteers for B12019, a New Proposed Pegfilgrastim Biosimilar

Blood, 2016
Dirk Lehnick
exaly